Frontier Medicines
The AI engine Fit Assessment
BetaFrontier Medicines effectively leverages machine learning to discover new patterns in protein interactions and expand therapeutic options, optimizing the drug discovery process.
Blurb
Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.
HQ Location
United States
Founded
2018
Employees
51 - 200
Total funding raised
$255.50M
Last Funding Event
Series C, $20.00M, June 25, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Developer of a chemoproteomics platform designed to accelerate the development of medicines. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling healthcare professionals to provide medicines to patients that redefine the course of debilitating diseases.